14
Dec
2018
Allen’s $125M Bet on Immunology, Gilead’s New CEO, & Insulin Price-Gouging Scrutiny
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account. 
Share:
12
Dec
2018
First Everest, Now Kilimanjaro: Climb With Me and a Great Biotech Team to Fight Cancer
Summiting the highest peak in the world and raising $340,000 for cancer research at Fred Hutch was the start. It was the start of something bigger. Today, I’m overjoyed to say that an outstanding team of biotech executives and investors will join me on the Kilimanjaro Climb to Fight Cancer. This will be a 7-day expedition to the summit of...Read More
Share:
11
Dec
2018
Google Money at Work in Biology: Krishna Yeshwant on The Long Run
Today’s guest on The Long Run is Krishna Yeshwant. Krishna is a general partner with GV, the corporate venture firm formerly known as Google Ventures. He is a rare bird – a Stanford computer scientist and a Harvard physician. With this combination of professional interests, and with the resources of Google to invest in fledgling companies, Krishna has acquired an...Read More
Share:
11
Dec
2018
OSI Veterans, and Versant Ventures, Unveil Startup To Fight Allosteric Resistance Mutations in Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
30
Nov
2018
CRISPR Babies, Ireland’s Bold Genomics Move, and a Flurry of FDA Approvals
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
28
Nov
2018
Extending Human Healthspan: Ned David of Unity Biotech on The Long Run
Today’s guest on The Long Run is Nathaniel David. He goes by Ned for short. Ned is the co-founder and president of Unity Biotechnology. The company, founded in 2011 and based in Brisbane, Calif., comes from an emerging school of thought around clearing out senescent cells. The wager at Unity is that by clearing out these senescent cells that accumulate...Read More
Share:
16
Nov
2018
Moderna’s Mega-IPO Plan, AbbVie Nails HCV, & SVB Takes Out Leerink
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
15
Nov
2018
China Biotech: Six Things to Watch in 2019
More than $1.5 billion in cash flooded into four IPOs offerings for China-based drug developers this year. These were just the first. The China biotech IPO opening was — and will continue to be — a big ongoing story. In April, the Hong Kong Stock Exchange relaxed rules allowing public stock investment in pre-revenue (development-stage) biotech companies. In July, the...Read More
Share:
14
Nov
2018
From Nova Scotia to the Forefront of Bio & Tech Investing: Julie Sunderland of Biomatics on The Long Run
Julie Sunderland is the guest on the latest episode of The Long Run podcast. She is a managing director at Biomatics Capital, a Seattle-based venture firm that invests in what it calls “data-enabled healthcare.” Before diving into that, as always, I want listeners to get to know the person making things happen, and how she got here. Sunderland her fellow...Read More
Share:
9
Nov
2018
Sage Postpartum Depression Drug Passes Scrutiny, Blavatnik’s $200M Beneficence, & A Novartis Pricing Trial Balloon
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
2
Nov
2018
Illumina Takes Out PacBio, AbbVie’s Pre-Emptive Price Cut, & HHS Drug Pricing Guy Dies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
1
Nov
2018
Exploring Synthetic Lethal Cancer Drug Discovery: Barbara Weber on The Long Run
Today’s guest on The Long Run podcast is Barbara Weber. She is the CEO of Cambridge, Mass.-based Tango Therapeutics. Ever hear the saying ‘it takes two to tango?’ That’s where this startup draws its inspiration. It’s seeking to discover and develop synthetic lethal cancer drugs. These are intended to target two molecular vulnerabilities of a cancer cell, not just one,...Read More
Share:
30
Oct
2018
Nine VCs Who Matter, But You Never Read About
Venture capitalists see a steady stream of people asking for money and currying favor. This can inflate the ego to unhealthy proportions. The best VCs, however, don’t let all that get to their head. They also don’t just write checks. They help entrepreneurs. Quite a few of the best VCs in biotech tend to work behind the scenes. You don’t...Read More
Share:
26
Oct
2018
Amgen’s Price Cut, Biogen-Eisai Alzheimer’s Whiff, & a New Osteoarthritis Drug
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
19
Oct
2018
Novartis’ $2B Takeover of Endocyte, Revolution-Warp Drive, & Amgen’s Foray in DNA Sequencing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
18
Oct
2018
AbbVie Plunks Down $100M Upfront for Morphic’s Oral Integrin Inhibitors for Fibrosis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
17
Oct
2018
Making it Easy to Share Biological Data: John Wilbanks on The Long Run Podcast
John Wilbanks is today’s guest on The Long Run podcast. He’s the chief commons officer of Sage Bionetworks. He’s also a senior fellow with FasterCures. Sage, for those unfamiliar, is a nonprofit biomedical research organization, founded in Seattle in 2009 by a couple of veterans of Merck. Co-founders Stephen Friend and Eric Schadt recognized that no single company’s R&D labs,...Read More
Share:
12
Oct
2018
Allogene’s Megabucks IPO, CVS-Aetna Muscling Through, & Consumer Genetics in the Mainstream
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
11
Oct
2018
The MIT Biotech Group Alumni: Where Are They Now?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
5
Oct
2018
Nobel Highlights and Lowlights, MSK Fallout Continues, Pfizer CEO Stepping Down
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share: